Patrick M. Travis

620 total citations
10 papers, 482 citations indexed

About

Patrick M. Travis is a scholar working on Genetics, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Patrick M. Travis has authored 10 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Genetics, 4 papers in Immunology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Patrick M. Travis's work include Chronic Lymphocytic Leukemia Research (4 papers), Immunodeficiency and Autoimmune Disorders (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). Patrick M. Travis is often cited by papers focused on Chronic Lymphocytic Leukemia Research (4 papers), Immunodeficiency and Autoimmune Disorders (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). Patrick M. Travis collaborates with scholars based in United States and Lebanon. Patrick M. Travis's co-authors include Chandra P. Belani, Hak Choy, John J. Haluschak, Walter J. Curran, P. Bonomi, Charles Scott, Martin Hauer‐Jensen, Peter Sportelli, Hari P. Miskin and Jeff P. Sharman and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Current topics in microbiology and immunology.

In The Last Decade

Patrick M. Travis

10 papers receiving 468 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patrick M. Travis United States 8 352 233 60 52 51 10 482
Anthea Lau Canada 9 154 0.4× 158 0.7× 40 0.7× 105 2.0× 127 2.5× 28 413
Prashant Gabani United States 12 188 0.5× 156 0.7× 71 1.2× 28 0.5× 20 0.4× 28 342
Emilie Bogart France 12 242 0.7× 107 0.5× 109 1.8× 39 0.8× 22 0.4× 35 437
P. Dickinson United Kingdom 11 208 0.6× 208 0.9× 107 1.8× 62 1.2× 30 0.6× 22 471
Haruhito Kamei Japan 9 465 1.3× 389 1.7× 21 0.3× 37 0.7× 22 0.4× 37 573
Liberato Di Lullo Italy 10 110 0.3× 189 0.8× 55 0.9× 30 0.6× 16 0.3× 24 321
H. Selim United States 8 376 1.1× 286 1.2× 64 1.1× 21 0.4× 108 2.1× 12 496
Loredana Costa Italy 11 202 0.6× 176 0.8× 37 0.6× 28 0.5× 69 1.4× 29 496
Virag Dandekar United States 4 151 0.4× 234 1.0× 43 0.7× 24 0.5× 26 0.5× 6 527
Noriko Ii Japan 13 200 0.6× 146 0.6× 73 1.2× 46 0.9× 49 1.0× 40 519

Countries citing papers authored by Patrick M. Travis

Since Specialization
Citations

This map shows the geographic impact of Patrick M. Travis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick M. Travis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick M. Travis more than expected).

Fields of papers citing papers by Patrick M. Travis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick M. Travis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick M. Travis. The network helps show where Patrick M. Travis may publish in the future.

Co-authorship network of co-authors of Patrick M. Travis

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick M. Travis. A scholar is included among the top collaborators of Patrick M. Travis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick M. Travis. Patrick M. Travis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Li, Daneng, Anthony F. Shields, Hirva Mamdani, et al.. (2024). Oncolytic virus CF33-hNIS monotherapy for the treatment of gastrointestinal (GI) malignancies.. Journal of Clinical Oncology. 42(3_suppl). 749–749. 1 indexed citations
2.
Sharman, Jeff P., Danielle M. Brander, Anthony R. Mato, et al.. (2021). Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. The Lancet Haematology. 8(4). e254–e266. 39 indexed citations
3.
Sharman, Jeff P., Danielle M. Brander, Anthony R. Mato, et al.. (2020). Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study.. Journal of Clinical Oncology. 38(15_suppl). 8022–8022. 7 indexed citations
4.
Sharman, Jeff P., Danielle M. Brander, Anthony R. Mato, et al.. (2017). Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study.. Journal of Clinical Oncology. 35(15_suppl). 7504–7504. 7 indexed citations
5.
Sharman, Jeffrey P., Danielle M. Brander, Anthony R. Mato, et al.. (2017). UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY. Hematological Oncology. 35(S2). 111–112. 4 indexed citations
6.
Hoff, Daniel D. Von, Laura A. Marlow, Christina A. Von Roemeling, et al.. (2011). An Effective Personalized Approach to a Rare Tumor: Prolonged Survival in Metastatic Pancreatic Acinar Cell Carcinoma Based on Genetic Analysis and Cell Line Development. Journal of Cancer. 2. 142–152. 23 indexed citations
7.
Belani, Chandra P., Hak Choy, P. Bonomi, et al.. (2005). Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non–Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol. Journal of Clinical Oncology. 23(25). 5883–5891. 328 indexed citations
8.
9.
Travis, Patrick M., et al.. (1997). Mode of chemotherapy does not affect complications with an implantable venous access device. Cancer. 80(5). 966–972. 31 indexed citations
10.
Hoover, R G, et al.. (1995). c-myc Transcription is Initiated from Po in 70% of Patients with Multiple Myeloma. Current topics in microbiology and immunology. 194. 257–264. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anthea Lau Breakdown of academic impact, for papers by Prashant Gabani Breakdown of academic impact, for papers by Emilie Bogart Breakdown of academic impact, for papers by P. Dickinson Breakdown of academic impact, for papers by Haruhito Kamei Breakdown of academic impact, for papers by Liberato Di Lullo Breakdown of academic impact, for papers by H. Selim Breakdown of academic impact, for papers by Loredana Costa Breakdown of academic impact, for papers by Virag Dandekar Breakdown of academic impact, for papers by Noriko Ii
Rankless by CCL
2026